INNOCARE (688428.SH): Releases Phase II Clinical Data of Novel BTK Inhibitor Obutinib on Forum.
Nuocheng Jianhua (688428.SH) announced that the company will attend the 10th Americas Multiple Sclerosis Annual Meeting in 2025...
INNOCARE (688428.SH) announced that at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in 2025, they will present Phase II clinical data for a new BTK inhibitor, orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis (RRMS). The data will be presented in a live poster session on February 27th, Eastern Time (poster code: P094).
The research results demonstrate that orelabrutinib has shown high efficacy in treating RRMS patients. The daily dose of 80mg orelabrutinib once a day has shown the best therapeutic effects and safety, and will therefore be used as the dosage for the Phase III clinical trial of orelabrutinib in treating progressive multiple sclerosis (PMS).
Related Articles
HK Stock Market Move | POLY PPT SER(06049) rose over 3% in the afternoon. Last year, net profit increased by 5.1% compared to the previous year, with the final dividend increasing to 1.401 yuan.
HK Stock Market Move | PATEO (02889) soared more than 25% in the afternoon, with high-end cabins continuing to see a surge in sales. The company's annual revenue increased by over 37% year-on-year.
Subversion in Progress: Deutsche Bank Warns Consumer Goods Industry of End of "Traditional Defense Logic", Five Major Headwinds Reshaping Landscape
HK Stock Market Move | POLY PPT SER(06049) rose over 3% in the afternoon. Last year, net profit increased by 5.1% compared to the previous year, with the final dividend increasing to 1.401 yuan.
HK Stock Market Move | PATEO (02889) soared more than 25% in the afternoon, with high-end cabins continuing to see a surge in sales. The company's annual revenue increased by over 37% year-on-year.
Subversion in Progress: Deutsche Bank Warns Consumer Goods Industry of End of "Traditional Defense Logic", Five Major Headwinds Reshaping Landscape
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
